Key result
The PanCareSurFup cardiac study methodology establishes a pan-European cohort of 59,915 5-year childhood cancer survivors to investigate the incidence and risk factors for symptomatic cardiac events.
Why the study?
What are the incidence and treatment-related risk factors for developing symptomatic cardiac events in 5-year childhood cancer survivors?
Cohort (n=59,915)
Yes
What are the incidence and treatment-related risk factors for developing symptomatic cardiac events in 5-year childhood cancer survivors?
The PanCareSurFup cardiac study methodology establishes a large pan-European cohort of 59,915 childhood cancer survivors to systematically evaluate the incidence and risk factors of late symptomatic cardiac events.
Provides foundation for quantifying late cardiac events in survivors; leaves open incidence and risk estimates pending outcome data.
BACKGROUND AND AIM: Childhood cancer survivors are at high risk of long-term adverse effects of cancer and its treatment, including cardiac events. The pan-European PanCareSurFup study determined the incidence and risk factors for cardiac events among childhood cancer survivors. The aim of this article is to describe the methodology of the cardiac cohort and nested case-control study within PanCareSurFup. METHODS: Eight data providers in Europe participating in PanCareSurFup identified and validated symptomatic cardiac events in their cohorts of childhood cancer survivors. Data on symptomatic heart failure, ischemia, pericarditis, valvular disease and arrhythmia were collected and graded according to the Criteria for Adverse Events. Detailed treatment data, data on potential confounders, lifestyle related risk factors and general health problems were collected. RESULTS: The PanCareSurFup cardiac cohort consisted of 59,915 5-year childhood cancer survivors with malignancies diagnosed between 1940 and 2009 and classified according to the International Classification of Childhood Cancer 3. Different strategies were used to identify cardiac events such as record linkage to population/ hospital or regional based databases, and patient- and general practitioner-based questionnaires. CONCLUSION: The cardiac study of the European collaborative research project PanCareSurFup will provide the largest cohort of 5-year childhood cancer survivors with systematically ascertained and validated data on symptomatic cardiac events. The result of this study can provide information to minimize the burden of cardiac events in childhood cancer survivors by tailoring the follow-up of childhood cancer survivors at high risk of cardiac adverse events, transferring this knowledge into evidence-based clinical practice guidelines and providing a platform for future research studies in childhood cancer patients. .
No takes yet. Share an insight, caveat, or question.
Feijen et al. (2016) conducted a cohort in Childhood cancer survivors at risk for late cardiac events (n=59,915). Childhood cancer treatments (chemotherapy, radiotherapy) vs. Survivors without cardiac events (nested case-control) was evaluated on Symptomatic heart failure, cardiac ischemia, pericarditis, valvular disease and arrhythmia (CTCAE grade 3-5). The PanCareSurFup cardiac study methodology establishes a pan-European cohort of 59,915 5-year childhood cancer survivors to investigate the incidence and risk factors for symptomatic cardiac events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: